EXCLUSIVE PATENT LICENSE AGREEMENT
Exhibit 10.1
This
Exclusive Patent License Agreement is made as of July 27, 2009 (“Effective Date”) between
Ensisheim Partners, LLC, a Washington limited liability company (“Licensor”), and Atossa
Genetics, Inc., a Delaware corporation (“Atossa”). The parties agree as
follows:
1. DEFINITIONS
1.1 “First Commercial Sale” means
the initial transfer of a Licensed Product by Atossa, an affiliate or a
sublicensee to a third party in exchange for cash or some equivalent to which
value can be assigned in any country after all required marketing and pricing
approvals have been granted, or otherwise permitted, by the authorities of such
country, in each case for use or consumption of such Licensed Product in such
country by the general public. Sales for test marketing, sampling and
promotional uses, clinical trial purposes, or compassionate or similar use will
not be considered a First Commercial Sale.
1.2 “Licensed Patents” means: (a)
all patents and patent applications set forth in Exhibit A; (b) all
divisions, substitutions, continuations, continuation-in-parts, reissues,
reexaminations, and extensions of the patents and patent applications described
in Section 1.1(a); (c) all foreign and
international counterparts of the patents and patent applications described in
Sections 1.1(a) and 1.1(b); and (d) all patents issuing from patent
applications described in Sections 1.1(a), 1.1(b), and 1.1(c).
1.3 “Licensed Product” means any
product the manufacture, use, or sale of which would, in the absence of the
licenses granted in this Agreement, infringe a Valid Claim of a Licensed Patent
in the country in which that product is made, used, or sold.
1.4 “Net Sales Revenues” means the
gross amount collected by Atossa for the sale of a Licensed Product, less all:
(a) normal and customary cash and trade discounts and rebates (including prompt
payment and volume discounts); (b) duties and taxes (including excise, sales,
use, and value added taxes); (c) insurance, freight, packaging, handling,
shipment, and transportation expenses (including associated insurance costs);
(d) amounts allowed or credited due to returns, rejections, recalls, rebates,
charge backs, billing errors, or retroactive price reductions; and (e) sales
commissions or fees paid. Net Sales Revenues excludes amounts collected by
Atossa: (i) that are not directly related to sale of a Licensed Product,
including amounts paid for support, maintenance, development, research, clinical
trials, training, and products bundled with a Licensed Product; (ii) for
transfers made to a third party for resale by the third party or to an
affiliate; and (iii) for Licensed Products used for research and development or
other non-commercial uses, supplied as commercial samples, or supplied as
charitable donations.
1.5 “Valid Claim” means a pending
or issued and unexpired claim of a Licensed Patent so long as that claim has not
been: (a) irrevocably abandoned, withdrawn, or declared to be unpatentable,
invalid, or unenforceable in an unappealable decision of a court or other
authority of competent jurisdiction; or (b) found or admitted to be invalid or
unenforceable through no fault or cause of Atossa, whether through reissue,
re-examination, disclaimer or otherwise.
2. GRANT
OF RIGHTS
2.1 Licensed Patents.
Licensor hereby grants to Atossa and its affiliates an exclusive, worldwide,
perpetual, irrevocable, royalty-bearing (as set forth in Section 3), license, with the right to grant and authorize
sublicenses, under the Licensed Patents to do the following: (a) make, have
made, use, sell, offer to sell, export, import, and otherwise distribute
Licensed Products; (b) practice and perform any processes, methods, and
procedures described in or that would infringe a Valid Claim of a Licensed
Patent; and (c) otherwise exploit the Licensed Patents.
2.2 Exclusivity. The
license granted in Section 2.1 is exclusive in that
Licensor must not, directly or indirectly: (a) exercise or grant to any third
party any license or other right under a Licensed Patent; or (b) develop or sell
any products or services in the Exclusive Field that would infringe a Licensed
Patent. Without limiting Atossa’s rights or remedies at law, and without regard
to whether Atossa has an adequate remedy at law, Atossa will have the right to
seek equitable relief to prevent any breach or threatened breach of this
Section 2.2.
2.3 Ownership of Licensed
Patents. Licensor will at all times be the sole owner of all right,
title, and interest (including intellectual property rights) in and to the
Licensed Patents.
2.4 No Requirements.
Atossa is not required to: (a) develop Licensed Products; (b) receive Licensor’s
or a third party’s approval for any use of any Licensed Products; (c) attribute
creation or development of any Licensed Product to Licensor; or (d) take action
against any third party relating to the third party’s use or exploitation of any
Licensed Product.
2.5 Rights in Bankruptcy.
All rights and licenses granted under or pursuant to this Agreement by Licensor
to Atossa are, and will otherwise be deemed to be, for purposes of Section
365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual
property” as defined under Section 101(56) of the Bankruptcy Code. Atossa, as a
licensee of the rights under this Agreement, will retain and may fully exercise
all of its rights and elections under the Bankruptcy Code.
3. ROYALTY
3.1 Royalty Rate. Subject
to Section 3.2, Atossa will pay Licensor a royalty
equal to two percent (2%) of Net Sales Revenues (“Licensing Royalty”). No more
than one royalty payment will be due under this Agreement with respect to a sale
of a particular Licensed Product, even if that Licensed Product is covered by
multiple Valid Claims.
3.2 Minimum
Royalty. Atossa will pay Licensor, in accordance with this
Section, a minimum royalty of $12,500 per fiscal quarter during the term of this
Agreement, which will increase to a minimum royalty of $25,000 per fiscal
quarter beginning in the quarter in which the First Commercial Sale of a
Licensed Product takes place (each, a “Minimum Royalty”). Atossa will
pay Licensor a pro-rata portion of the first Minimum Royalty within 30 days of
the Effective Date, and the Minimum Royalty for each subsequent fiscal quarter
will be due upon the first day of that fiscal quarter. The Minimum Royalty for
any given fiscal quarter is creditable against any Licensing Royalties due in
that fiscal quarter.
-2-
3.3 Reduction for Third Party
Payments. If Atossa’s manufacture, sale, use, importation, or other
exploitation of a Licensed Product is subject to one or more patents owned,
controlled, or licensable by a third party and Atossa pays the third party to
license such patents, then the Licensing Royalty will be reduced by the amount
paid to the third party for such license, except that the Licensing Royalty
payable to Licensor will not fall below 1% of Net Sales Revenues during any
fiscal quarter.
3.4 Reporting and
Payment. No later than 60 days after the end of each fiscal quarter
during the term of this Agreement, Atossa will deliver to Licensor a written
report of the Net Sales Revenues collected during the fiscal quarter. With each
report submitted by Atossa, Atossa will deliver payment of the Licensing Royalty
due for the applicable fiscal quarter to the extent not covered by any other
payments made by Atossa that are creditable against Licensing Royalty payments,
e.g., the applicable Minimum Royalty payment.
4. PROSECUTION
AND MAINTENANCE OF THE LICENSED PATENTS
4.1 Atossa’s Rights.
Licensor grants to Atossa: (a) the right to prepare, file, prosecute, and
maintain, in its own name and at its own expense, the Licensed Patents in any
country; and (b) an irrevocable power of attorney to act on Licensor’s behalf
and to execute and file documents on Licensor’s behalf to prepare, file,
prosecute, and maintain these rights.
4.2 Licensor’s
Obligations. Licensor will consult with Atossa regarding the preparation,
filing, prosecution, and maintenance of the Licensed Patents. Licensor will not
prepare, file, prosecute, or maintain the Licensed Patents without Atossa’s
prior written consent. Licensor will have the right to prepare, file, prosecute,
and maintain, in its own name and at its own expense, the Licensed Patents in
any country where Atossa fails or declines to prosecute or maintain those
rights. Licensor may exercise this right only if it notifies Atossa of its
intent in writing and Atossa does not proceed to prosecute or maintain those
rights within 60 days after the notice. Licensor will keep Atossa reasonably
informed regarding Licensor’s prosecution and maintenance of the Licensed
Patents in accordance with this Section (e.g., status of patent filings and
registrations).
5. ENFORCEMENT
OF LICENSED PATENTS
5.1 Atossa’s Rights.
Licensor grants to Atossa the right to bring and prosecute lawsuits against
third parties, in Atossa’s own name or jointly with Licensor if required by law,
for infringement of a Licensed Patent. This right includes bringing any legal
action for infringement, defending any counter claim of invalidity or action of
a third party for declaratory judgment for non-infringement or non-interference,
and settling a suit. Atossa will be entitled to all of the damages, profits, and
awards of whatever nature recoverable from the suit. Licensor will fully
cooperate with Atossa in the prosecution of any such lawsuit at Atossa’s
expense.
5.2 Licensor’s
Obligations. Licensor will not bring or prosecute a lawsuit against any
third party for infringement of a Licensed Patent without Atossa’s prior written
consent. In addition, if Atossa does not institute a lawsuit (including, but not
limited to, temporary and permanent injunctive actions) within a reasonable
period, but no more than 60 days following Licensor’s written request to do so,
Licensor will have the right to institute and
-3-
prosecute
the lawsuit in its own name or jointly with Atossa if required by law. Atossa
will fully cooperate with Licensor in the prosecution of any such lawsuit at
Licensor’s expense.
6. TERM
AND TERMINATION
6.1 Term. This Agreement
will take effect on the Effective Date and will continue in effect, on a
country-by-country basis, until the date on which no further Licensing Royalty
would be due in such country, unless terminated earlier in accordance with the
terms of this Agreement.
6.2 Termination by Atossa for
Convenience. Atossa may terminate this Agreement, in whole or as to any
particular Licensed Patent or Licensed Product, for any reason or for no reason
by notifying Licensor in writing. Termination in accordance with this Section 6.2 will take effect five days after Licensor receives
Atossa’s written notice of termination.
6.3 Effects of Termination or
Expiration
(a) Payment or Refund.
Within 60 days after termination or expiration of the Agreement, Atossa will pay
to Licensor all Licensing Royalties that it owes for sale of Licensed Products
prior to the date of termination or expiration.
(b) Survival. All rights
and duties of the parties under this Agreement will terminate upon termination
or expiration of this Agreement for any reason except that: (i) all sublicenses
granted by Atossa prior to termination or expiration will survive termination;
and (ii) Sections 6.3 and 8 will survive termination or expiration of this
Agreement.
7. REPRESENTATIONS
AND WARRANTIES
7.1 Authorization.
Licensor represents and warrants that: (a) it is duly organized, validly
existing, and in good standing in the jurisdiction stated in the preamble to
this Agreement; (b) the execution and delivery of this Agreement by Licensor has
been duly and validly authorized; and (c) this Agreement constitutes a valid,
binding, and enforceable obligation of Licensor.
7.2 No Conflict. Licensor
represents and warrants that: (a) the execution of this Agreement and Licensor’s
performance under this Agreement does not and will not violate, conflict with,
or result in a material default under any other agreement, indenture, decree,
judgment, lien, or encumbrance to which Licensor is a party or by which any of
the Licensed Patents are or may become subject or bound; (b) Licensor has not
granted any other rights under the Licensed Patents; and (c) Licensor will not
grant any rights under any future agreement, nor will it permit or suffer any
lien, obligation, or encumbrances, that will conflict with the full enjoyment by
Atossa of its rights under this Agreement.
7.3 Validity and
Enforceability. Licensor represents and warrants that: (a) to Licensor’s
knowledge, Licensor’s rights to the Licensed Patents are valid and enforceable;
and (b) Licensor does not know of any facts or circumstances that could impair
the validity or enforceability of any of its rights to the Licensed
Patents.
-4-
7.4 Legal Proceedings.
Licensor represents and warrants that: (a) Licensor is not involved in any legal
proceeding (litigation, arbitration, mediation, or otherwise) relating to the
Licensed Patents; (b) Licensor has not received notice of a claim relating to
the Licensed Patents; and (c) Licensor is not aware of any facts or
circumstances that might lead to a legal proceeding relating to the Licensed
Patents.
8. GENERAL
8.1 Remedies
(a) No Consequential
Damages. IN NO EVENT WILL EITHER PARTY HAVE LIABILITY TO THE OTHER PARTY
FOR ANY INDIRECT, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES, EVEN IF ADVISED
OF THE POSSIBILITY OF THESE DAMAGES. THESE LIMITATIONS WILL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY
IN THIS AGREEMENT.
(b) Limitation to
Damages. Licensor’s sole remedy, if any, in the event of a breach will be
an action for monetary damages. Licensor will not be entitled to injunctive or
other equitable relief or to terminate or rescind this Agreement or the licenses
granted in this Agreement.
8.2 Relationship. Nothing
in this Agreement may be construed as creating an employer-employee
relationship, agency relationship, joint venture, or partnership between the
parties.
8.3 Assignability.
Neither this Agreement nor any rights or obligations under this Agreement may be
assigned or otherwise transferred by Licensor, in whole or in part, whether
voluntarily or by operation of law, without the prior written consent of Atossa.
Atossa may assign this Agreement or any rights and obligations under this
Agreement freely. Subject to the foregoing, this Agreement will be binding upon
and will inure to the benefit of the parties and their respective successors and
assigns. Any assignment in violation of the foregoing will be null and
void.
8.4 Further Assurances.
Each party agrees that it will execute and deliver such documents as may be
required to implement any of the provisions of this Agreement.
8.5 Governing Law. This
Agreement is governed by the laws of the State of Washington, without giving
effect to provisions related to choice of laws or conflict of laws.
8.6 Venue and
Jurisdiction. Venue and jurisdiction of any lawsuit involving this
Agreement exists exclusively in the state and federal courts in King County,
Washington, unless Atossa seeks injunctive relief that, in Atossa’s judgment,
would not be effective unless obtained in some other venue.
8.7 Waiver. The waiver by
either party of any breach of any provision of this Agreement does not waive any
other breach. The failure of any party to insist on strict performance of any
covenant or obligation under this Agreement will not be a waiver of such
-5-
party’s
right to demand strict compliance in the future, nor will the same be construed
as a novation of this Agreement.
8.8 Severability. If any
part of this Agreement is found to be unenforceable, the remaining portions of
this Agreement will remain in full force and effect.
8.9 Drafting. The parties
have had an equal opportunity to participate in the drafting of this Agreement
and the attached exhibits. No ambiguity will be construed against any party
based upon a claim that that party drafted the ambiguous
language.
8.10 Headings. The
headings appearing at the beginning of several sections contained in this
Agreement have been inserted for identification and reference purposes only and
must not be used to construe or interpret this Agreement.
8.11 Notices. Any notice
required or permitted to be given under this Agreement will be effective if it
is in writing and sent by certified or registered mail, or insured courier,
return receipt requested, to the appropriate party at the address set forth
below and with the appropriate postage affixed. Either party may change its
address for receipt of notice by notice to the other party in accordance with
this Section. Notices will be deemed given two business days following the date
of mailing or one business day following delivery to a courier.
|
To Licensor:
|
To Atossa:
|
|
Shu-Xxxx
Xxxx Quay
|
Xx.
Xxxxxx Xxxx
|
|
Ensisheim
Partners, LLC
0000
X Xxxxxxx Xx, Xxxxx 000
|
Xxxxxx
Genetics, Inc.
0000 X. Xxxxxxx Xx., Xxxxx 000
Xxxxxxx, XX 00000
|
|
Xxxxxxx,
XX 00000
|
|
|
With
a copy to:
Xx.
Xxxxx Xxxxxx, Esq.
Xxxxxx
Xxxxxxx Xxxxxxxx & Xxxxxx, PC
000
Xxxxx Xxx., Xxxxx 0000
Xxxxxxx,
XX 00000
|
8.12 Counterparts. This
Agreement may be executed in any number of identical counterparts,
notwithstanding that the parties have not signed the same counterpart, with the
same effect as if the parties had signed the same document. All counterparts
will be construed as and constitute the same agreement.
8.13 Entire Agreement.
This Agreement, including any exhibits, is the final and complete expression of
all agreements between these parties and supersedes all previous oral and
written agreements regarding these matters. It may be changed only by a written
agreement signed by the party against whom enforcement is sought.
|
“Licensor”
|
“Atossa”
|
|
Ensisheim
Partners, LLC
|
Atossa
Genetics, Inc.
|
|
Name:
Shu-Xxxx Xxxx Quay
|
Name:
Xx. Xxxxxx Xxxx
|
|
Title:
Principal
|
Title:
President
|
|
Signature: /s/
Shu-Xxxx Xxxx Quay
|
Signature:
/s/ Xxxxxx
Xxxx
|
|
Date:
27 July,
2009
|
Date:
27 July,
2009
|
-6-
EXHIBIT
A
LICENSED
PATENTS
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
ATOS-0003
US
(020424-000100US)
|
Methods
and Kits for Obtaining and Assaying Mammary Fluid Samples for Breast
Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
|
08/709,207
08/27/96
|
5,798,266
08/25/98
11.5
Yr MF-February 25, 2010
|
|
XXXX-0000
Xxxxxxxxx
(020424-000100AU)
|
Methods
and Kits for Obtaining and Assaying Mammary Fluid Samples for Breast
Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(claims
priority to ATOS-0004 and ATOS-00003)
|
40850/97
08/22/97
|
740,160
13th
Yr MF-August 22, 2009
|
|
ATOS-0006
Canada
(020424-000100CA)
|
Methods
and Kits for Obtaining and Assaying Mammary Fluid Samples for Breast
Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(claims
priority to ATOS-0004 and ATOS-00003)
|
2,264,277
08/22/97
|
2,264,277
04/15/2008
13th
Yr MF-August 22, 2009
|
-7-
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
PCT
ATOS-0004?
|
Methods
and Kits for Obtaining and Assaying Mammary Fluid Samples for Breast
Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(claims
priority to ATOS-0004 and ATOS-00003)
Foreign
filing of ATOS-0003
|
PCT/US97/14863
filed
08/22/97
WO
98/08976 published 03/05/1998
|
NATIONAL
|
|
ATOS-0007
European
(020424-000100EP)
|
Kits
for Obtaining and Assaying Mammary Fluid Samples for Breast Diseases,
Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(claims
priority to ATOS-0004 and ATOS-00003)
|
97938551.5
08/22/97
Notice
of Intent to Grant
EU
Validation-November 8, 2008
|
EP
0932699 - withdrawn
January
8, 2009-2 Month Further Processing Request
|
|
ATOS-0025
Hong
Kong
(020424-000100HK)
|
Kits
for Obtaining and Assaying Mammary Fluid Samples for Breast Diseases,
Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(claims
priority to ATOS-0004 and ATOS-00003)
|
00100654.7
08/22/97
|
13th
Yr MF-August 22, 2009
|
-8-
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
ATOS-0026
Japan
(020424-000100JP)
|
Methods
and Kits for Obtaining and Assaying Mammary Fluid Samples for Breast
Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(claims
priority to ATOS-0004 and ATOS-00003)
|
10-511772
03/01/99
08/22/97
|
Abandoned
in Favor of CYTC-11-0407
|
|
ATOS-0027
US
(020424-000110US)
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(CIP
of ATOS-0003)
|
09/027,362
02/20/98
|
6,287,521
B1
09/11/01
7.5
Yr MF-March 11, 2009
|
|
ATOS-0028
US
(020424-000120US)
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(Cont.
of ATOS-0027 which is a CIP of ATOS-0003)
|
09/435,131
11/05/99
|
Abandoned
|
-9-
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
ATOS-0040
US
|
Devices
and Methods for Obtaining Mammary Fluid Samples for Evaluating Breast
Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(Utility
filing of ATOS-0030 and ATOS-0033
|
10/002,540
11/13/01
|
6,887,210
05/03/2005
|
|
ATOS-0041
US
|
Methods
and Devices for Collecting, Handling and Processing Mammary Fluid Samples
for Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(Utility
filing of ATOS-0030 and ATOS-0033
|
10/001,041
11/13/01
|
6,689,073
02/10/2004
|
|
US
|
Methods
and Devices for Collecting, Handling and Processing Mammary Fluid Samples
for Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
|
60/248,134
11/13/00
|
EXPIRED
|
-10-
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
US
|
Methods
and Devices for Collecting, Handling and Processing Mammary Fluid Samples
for Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
|
60/248,136
11/13/00
|
EXPIRED
|
|
ATOS-0042
PCT
|
Methods
and Devices for Collecting, Handling and Processing Mammary Fluid Samples
for Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(foreign
filing of ATOS-0030 and ATOS -0033 both filed 11/13/00)
|
PCT/US01/46032
11/13/01
Publication
No.
WO
02/38032 A2 on May 16, 2002
|
NATIONAL
|
|
ATOS-0043
Australia
|
Methods
and Kits for Obtaining and Assaying Mammary Fluid Samples for Breast
Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(Divisional
of ATOS-0005 which claims priority to ATOS-0004 and
ATOS-0003)
|
14725/02
01/31/02
|
781,187
13th
Yr MF- August 22, 2009
|
-11-
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
ATOS-0070
U.S.
Utility
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
Xxxxx
X. Xxxx
(Cont.
of ATOS-0028, which is a cont. of ATOS-0027, which is a CIP of
ATOS-0003)
|
10/404,866
Filed
3/31/03
|
7,128,877
10/31/2006
|
|
US
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
|
11/116,961
04/27/2005
|
Abandoned
|
|
JP
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(claims
priority to ATOS-0042, 60/248,134 & 60/248,136)
|
2003-343663
03/24/2004
11/13/2001
|
-12-
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
CA
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(claims
priority to ATOS-0042, 60/248,134 & 60/248,136)
|
2,427,967
08/22/1997
11/13/2001
|
2,427,967
8th
Yr MF – November 13, 2008
|
|
EP
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(claims
priority to ATOS-0042, 60/248,134 & 60/248,136)
|
01993422.3
11/13/2001
|
|
|
JP
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(claims
priority to ATOS-0042, 60/248,134 & 60/248,136)
|
11/13/2001
4,050,612
|
4,050,612
10th
Yr MF – November 13, 2008
|
-13-
|
WWKMN
Ref.
(TTC
Ref. No.)
Country
|
Title
|
Inventor(s)
Priority
|
Application
Number
Filing
Date
|
Patent
Number
Issue
Date
Due:
|
|
AU
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(claims
priority to ATOS-0042, 60/248,134 & 60/248,136)
|
2002-227163
11/13/2001
|
8th
Yr MF – November 13, 2008
|
|
HK
|
Methods
and Devices for Obtaining and Assaying Mammary Fluid Samples for
Evaluating Breast Diseases, Including Cancer
|
Xxxxxx
X. Xxxx
(claims
priority to ATOS-0042, 60/248,134 & 60/248,136)
|
03105927.4
11/13/2001
|
9th
Yr MF – August 19, 2009
|
-14-
